<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>High-dose steroids are the first line of treatment for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (aGVHD) </plain></SENT>
<SENT sid="1" pm="."><plain>Steroid <z:hpo ids='HP_0003198'>myopathy</z:hpo> is a debilitating steroid-induced complication that significantly impairs a patient's performance status </plain></SENT>
<SENT sid="2" pm="."><plain>To determine the frequency and severity of steroid <z:hpo ids='HP_0003198'>myopathy</z:hpo> and other steroid related complications in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) who developed grade &gt;or=2 aGVHD after allogeneic hematopoietic stem cell transplantation (HSCT), we performed a retrospective analysis </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were included in the analysis if they had a diagnosis of <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>, underwent an allogeneic HSCT between January 1996 and December 2001 and developed grade &gt;or=2 aGVHD that was treated with 2 mg/kg of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> and survived at least 100 days post transplant </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 70 patients fulfilled our inclusion criteria </plain></SENT>
<SENT sid="5" pm="."><plain>Steroid <z:hpo ids='HP_0003198'>myopathy</z:hpo> was identified in 29 (41%) patients </plain></SENT>
<SENT sid="6" pm="."><plain>Steroid <z:hpo ids='HP_0003198'>myopathy</z:hpo> was generally of moderate severity with severe debilitating steroid <z:hpo ids='HP_0003198'>myopathy</z:hpo> seen in only 3% of patients </plain></SENT>
<SENT sid="7" pm="."><plain>We concluded that steroid <z:hpo ids='HP_0003198'>myopathy</z:hpo> is a common complication of high-dose steroid therapy after allogeneic HSCT in <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Interventions aimed at preventing and treating this complication are warranted and need to be explored in prospective clinical trials </plain></SENT>
</text></document>